Gabriel N. Hortobagyi, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, gives their thoughts on how results from the Phase III NATALEE (NCT03701334) study showed a potential impact on long-term outcomes, and what the implications might be for the treatment landscape of early breast cancer. Dr Hortobagyi also notes any considerations for extended or personalized treatment strategies based on these findings. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.